Stem Cell Assay Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players Analysis- Merck, Thermo…
stemadminAdult Stem CellsNo comments

DataIntelo published a detailed report on Global Stem Cell Assay Market for the clients that wants to explore new market avenues, get in-depth insights on the market products, maximize their revenue, and review the strategies implemented by prominent players in the market. Key Players of the Stem Cell Assay Market MerckThermo Fisher ScientificGE HealthcareAgilent TechnologiesBio-Rad LaboratoriesPromegaCell BiolabsPerkinElmerMiltenyi BiotecHemoGenixBio-TechneSTEMCELL Get Sample of the Stem Cell Assay Report https://dataintelo.com/request-sample/?reportId=187000 Major Highlights of the Stem Cell Assay Market Report Product Segment Performance of Stem Cell Assay marketStem Cell Assay Market DriversStem Cell Assay Market RestraintsMarket OpportunitiesImpact of COVID-19 PandemicTechnological Advancements & InnovationsRegional LandscapeCompetitive Landscape Of Stem Cell Assay marketTop-winning Strategies Implemented The research team at DataIntelo has proximately monitored the market since 2017.

Read more
Merck Receives Positive EU CHMP Opinion for Updated Label of KEYTRUDA (pembrolizumab) To Include Results of Phase 3 KEYNOTE-361 Trial in Certain Adult…
stemadminAdult Stem CellsNo comments

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that the European label for KEYTRUDA, Mercks anti-PD-1 therapy, be updated to include data from KEYNOTE-361, a Phase 3, open-label trial that evaluated KEYTRUDA as a monotherapy and in combination with chemotherapy for the first-line treatment of certain patients with advanced or metastatic urothelial carcinoma. In Europe, KEYTRUDA is approved for the treatment of adult patients with advanced or metastatic urothelial carcinoma (bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 with a Combined Positive Score (CPS) 10.

Read more
BioRestorative Therapies Announces Notices of Allowance for Three Patent Applications for its Off-the-Shelf ThermoStem Program – BioSpace
stemadminAdult Stem CellsNo comments

MELVILLE, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the United States Patent Office and several International agencies have issued notices of allowance for three separate patent applications related to the Companys metabolic ThermoStem Program.

Read more
We grew human tear glands in the lab, and now we’re making them cry – Down To Earth Magazine
stemadminAdult Stem CellsNo comments

Around 5% of the adult population suffer from dry eye syndrome because their tear glands don't function properly Most organs in the adult human body are capable of regeneration, which means they renew their cells to keep the tissue healthy and functional. This capacity is enabled by adult stem cells, which are present in most organs and divide to create new cells that replace older, damaged ones

Read more

Theme: Illdy.